MarketInOut Stock Screener Log In | Sign Up

AN2 Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/18/2026 16:00
AN2 Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization194.27 mln
Float28.29 mln
Earnings Date03/31/2027

Piotroski F-Score

3 / 9
Below average

Relative Strength

99 / 100
Top performer

ROE

-53.35
Deeply negative

ROA

-48.47
Deeply negative

Business Description

AN2 Therapeutics is a drug development company based in Menlo Park, California, that uses its boron chemistry platform to create new treatments for infectious diseases and cancer. Its lead drug, epetraborole, is currently in late-stage clinical trials as a daily oral pill for patients with non-tuberculous mycobacterial lung disease and is also being explored as a treatment for acute melioidosis. The company has additional programs in early development, including a treatment for chronic Chagas disease, and holds licensing partnerships with Anacor Pharmaceuticals, Brii Biosciences, and GSK to support the development and commercialization of its compounds across multiple markets.

Key Fundamentals

EPS-0.91
ROE-53.35
ROIC-753
ROA-48.47
EBITDA, mln-36.28
EV / EBITDA-3.08
EV / EBIT-3.08

Quote Details

Last 4.95
Change 0.72 (17.02%)
Open 4.40
Volume 967,184
Turnover 4,787,560
Average Volume 287,996

Financial Ratios

Leverage Ratio1.09
Current Ratio14.32
Price / Book1.89
Price / Tangible Book1.89

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio7.47
Short % of Float7.64

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.99% 98 / 100   
1 Month 39.04% 99 / 100   
2 Months -17.22% 19 / 100   
6 Months 7.84% 83 / 100   
1 Year 342% 100 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog